Physician profile
Javier E Alfonso
NPI 1093952442
$6,410.80
in general payments reported to CMS, 2019-2025
24 companies · $1,835 in 2025
The $1,835 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2021: $1,323 · 2022: $1,202 · 2023: $869 · 2024: $861 · 2025: $1,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,565.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,111.99 | 2021-2025 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $1,141.77 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $417.31 | 2024-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $298.24 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $277.33 | 2021-2022 | |
| Novo Nordisk INC | $268.00 | 2025 | Wegovy, Ozempic |
| Xeris Pharmaceuticals, INC. | $234.68 | 2021-2022 | |
| Lilly USA, LLC | $179.54 | 2025 | Zepbound, Jardiance |
| Insulet Corporation | $176.75 | 2019-2021 | |
| Outset Medical INC | $168.48 | 2024 | |
| Coloplast Corp | $151.26 | 2025 | |
| Glaxosmithkline, LLC. | $150.72 | 2024-2025 | Benlysta, Jesduvroq |
| Amgen INC. | $148.07 | 2019-2025 | Krystexxa, Tavneos |
| Mimedx Group, INC. | $143.16 | 2025 | |
| Mannkind Corporation | $125.00 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $124.99 | 2019 | |
| Fresenius USA Marketing, INC. | $124.80 | 2022 | |
| Shire North American Group INC | $44.03 | 2019 | |
| Janssen Pharmaceuticals, INC | $31.73 | 2019 | |
| Kyowa Kirin, INC. | $28.29 | 2024 | Crysvita |
| Travere Therapeutics, INC. | $20.62 | 2022 | |
| Abbvie INC. | $17.75 | 2022 | |
| Botanix Sb INC | $13.94 | 2025 | Sofdra |
| Journey Medical Corporation | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Alfonso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.